• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrazolopyridines

Methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (CAS No. 1527716-58-0): A Comprehensive Overview

Methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate, identified by its CAS number 1527716-58-0, is a significant compound in the realm of pharmaceutical chemistry. This heterocyclic molecule has garnered attention due to its structural complexity and potential biological activities. The compound belongs to the pyrazolo[1,5-a]pyridine scaffold, which is a privileged structure in medicinal chemistry known for its diverse pharmacological properties.

The< strong>name of the compound highlights its chemical composition, with the ester group (-COOCH?) and the methoxymethyl substituent (-OCH?CH?) playing crucial roles in determining its reactivity and biological interactions. The pyrazolo[1,5-a]pyridine core is a fused bicyclic system consisting of a pyrazole ring and a pyridine ring, which provides a unique framework for drug discovery. This scaffold has been extensively studied for its ability to modulate various biological pathways, making it a valuable candidate for developing novel therapeutic agents.

Recent advancements in chemical biology have shed new light on the potential applications of this compound. The< strong>methoxymethyl group, in particular, has been recognized for its ability to enhance solubility and bioavailability, which are critical factors in drug design. Additionally, the ester functionality at the 3-position of the pyrazolo[1,5-a]pyridine ring offers a versatile site for further chemical modifications, enabling the synthesis of derivatives with tailored pharmacological properties.

In the context of drug development, Methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate has been explored for its potential as an intermediate in the synthesis of more complex molecules. Its structural features make it a suitable precursor for generating compounds that target specific enzymes or receptors involved in disease pathways. For instance, studies have suggested that derivatives of this scaffold may exhibit inhibitory activity against kinases and other enzymes implicated in cancer and inflammatory diseases.

The< strong>CAS number 1527716-58-0 serves as a unique identifier for this compound, facilitating its recognition and use in research and industrial settings. The CAS registry system ensures that scientists worldwide can accurately reference and purchase this compound without ambiguity. This standardized naming convention is essential for maintaining consistency in chemical literature and patents.

One of the most intriguing aspects of Methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate is its potential role in modulating neurological pathways. The pyrazolo[1,5-a]pyridine core is known to interact with various neurotransmitter systems, suggesting that this compound could have applications in treating neurological disorders such as Alzheimer's disease and Parkinson's disease. Recent preclinical studies have demonstrated that certain derivatives of this scaffold exhibit neuroprotective effects by reducing oxidative stress and inflammation in neuronal cells.

The< strong>pharmacological profile of Methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate is further enhanced by its ability to cross the blood-brain barrier, which is crucial for developing effective central nervous system (CNS) drugs. This property has opened up new avenues for exploring its potential as a therapeutic agent against CNS disorders. Moreover, the compound's favorable pharmacokinetic properties, such as good oral bioavailability and metabolic stability, make it an attractive candidate for further development.

In conclusion, Methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (CAS No. 1527716-58-0) is a promising compound with significant potential in pharmaceutical research and drug development. Its unique structural features and biological activities make it a valuable tool for exploring new therapeutic strategies against various diseases. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the discovery and development of novel medicines.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)